Loading...
Effect of Pneumococcal Conjugate Vaccine on Pneumonia Incidence Rates among Children 2–59 Months of Age, Mongolia, 2015–2021
Зохиогч
Claire von Mollendorf
Munkhchuluun Ulziibayar
Cattram Duong Nguyen
Purevsuren Batsaikhan
Bujinlkham Suuri
Dashtseren Luvsantseren
Dorj Narangerel
John de Campo
Margaret de Campo
Sodbayar Demberelsuren
Eileen Margaret Dunne
Catherine Satzke
Tuya Mungun
Kim Mulholland
Он
2024 оны хоёрдугаар сарын 23
Төрөл
journal article
Хэвлэгч
Centers for Disease Control and Prevention
Journal
Emerging infectious diseases
Volume
30
Issue
3
Start Page
490
End Page
498
ISSN
1080-6040
1080-6059
Хураангуй
Starting in June 2016, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced into the routine immunization program of Mongolia by using a 2+1 dosing schedule, phased by district. We used prospective hospital surveillance to evaluate the vaccine's effect on pneumonia incidence rates among children 2-59 months of age over a 6-year period. Of 17,607 children with pneumonia, overall adjusted incidence rate ratios showed decreased primary endpoint pneumonia, very severe pneumonia, and probable pneumococcal pneumonia until June 2021. Results excluding and including the COVID-19 pandemic period were similar. Pneumonia declined in 3 districts that introduced PCV13 with catch-up campaigns but not in the 1 district that did not. After PCV13 introduction, vaccine-type pneumococcal carriage prevalence decreased by 44% and nonvaccine-type carriage increased by 49%. After PCV13 introduction in Mongolia, the incidence of more specific pneumonia endpoints declined in children 2-59 months of age; additional benefits were conferred by catch-up campaigns.